1. Home
  2. MGRX vs SHPH Comparison

MGRX vs SHPH Comparison

Compare MGRX & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mangoceuticals Inc.

MGRX

Mangoceuticals Inc.

HOLD

Current Price

$0.40

Market Cap

7.1M

Sector

Technology

ML Signal

HOLD

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

N/A

Current Price

$3.53

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MGRX
SHPH
Founded
2021
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
2.1M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
MGRX
SHPH
Price
$0.40
$3.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
824.5K
28.1K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
55.17
N/A
EPS
N/A
N/A
Revenue
$456,021.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.38
52 Week High
$2.75
$6.15

Technical Indicators

Market Signals
Indicator
MGRX
SHPH
Relative Strength Index (RSI) 44.55 48.36
Support Level $0.34 $3.29
Resistance Level $0.47 $4.64
Average True Range (ATR) 0.03 0.25
MACD -0.00 -0.04
Stochastic Oscillator 47.71 29.58

Price Performance

Historical Comparison
MGRX
SHPH

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Share on Social Networks: